Overview

Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI

Status:
Recruiting
Trial end date:
2027-03-01
Target enrollment:
Participant gender:
Summary
The objective of the proposed work is to determine whether administration for 12 months of romosozumab followed by 12 months of denosumab will maintain bone mass at the knee in subjects with chronic SCI.
Phase:
Phase 4
Details
Lead Sponsor:
James J. Peters Veterans Affairs Medical Center
Collaborator:
Kessler Institute for Rehabilitation
Treatments:
Denosumab